{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:00:17Z","timestamp":1771329617290,"version":"3.50.1"},"reference-count":297,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":1421,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PD\/BD\/128074\/2016"],"award-info":[{"award-number":["PD\/BD\/128074\/2016"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-0 31987"],"award-info":[{"award-number":["POCI-01-0145-FEDER-0 31987"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s13311-019-00798-1","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T15:02:41Z","timestamp":1572966161000},"page":"1009-1031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation"],"prefix":"10.1016","volume":"16","author":[{"given":"Jorge Diogo","family":"Da Silva","sequence":"first","affiliation":[]},{"given":"Andreia","family":"Teixeira-Castro","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcia","family":"Maciel","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1007\/s13311-019-00798-1_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1212\/WNL.30.3.319","article-title":"Clinical criteria for diagnosis of Machado-Joseph disease: report of a non-Azorena Portuguese family","volume":"30","author":"Lima","year":"1980","journal-title":"Neurology. United States"},{"key":"10.1007\/s13311-019-00798-1_bib2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/ng0793-300","article-title":"The gene for Machado-Joseph disease maps to human chromosome 14q","volume":"4","author":"Takiyama","year":"1993","journal-title":"Nat Genet. United States"},{"key":"10.1007\/s13311-019-00798-1_bib3","first-page":"221","article-title":"CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet","volume":"8","author":"Kawaguchi","year":"1994","journal-title":"United States"},{"key":"10.1007\/s13311-019-00798-1_bib4","first-page":"54","article-title":"Correlation between CAG repeat length and clinical features in Machado-Joseph disease","volume":"57","author":"Maciel","year":"1995","journal-title":"Am J Hum Genet. United States"},{"key":"10.1007\/s13311-019-00798-1_bib5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1006\/bbrc.1997.6484","article-title":"Machado-Joseph disease gene product identified in lymphocytes and brain","volume":"233","author":"Wang","year":"1997","journal-title":"Biochem Biophys Res Commun. United States"},{"key":"10.1007\/s13311-019-00798-1_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-6-35","article-title":"Machado-Joseph Disease: from first descriptions to new perspectives","volume":"6","author":"Bettencourt","year":"2011","journal-title":"Orphanet J Rare Dis. England"},{"key":"10.1007\/s13311-019-00798-1_bib7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1590\/0004-282X20140129","article-title":"Spinocerebellar ataxia type 3: subphenotypes in a cohort of Brazilian patients","volume":"72","author":"Moro","year":"2014","journal-title":"Arq Neuropsiquiatr. Brazil"},{"key":"10.1007\/s13311-019-00798-1_bib8","first-page":"17","article-title":"Machado-Joseph disease","volume":"3","author":"Sudarsky","year":"1995","journal-title":"Clin Neurosci. United States"},{"key":"10.1007\/s13311-019-00798-1_bib9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/archneur.58.2.296","article-title":"Spinocerebellar ataxia type 3 phenotypically resembling Parkinson disease in a black family","volume":"58","author":"Gwinn-Hardy","year":"2001","journal-title":"Arch Neurol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrn1474","article-title":"Pathways to motor incoordination: the inherited ataxias","volume":"5","author":"Taroni","year":"2004","journal-title":"Nat Rev Neurosci. England"},{"key":"10.1007\/s13311-019-00798-1_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/WCO.0b013e3282f7673d","article-title":"New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease)","volume":"21","author":"Rub","year":"2008","journal-title":"Curr Opin Neurol. England"},{"key":"10.1007\/s13311-019-00798-1_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.parkreldis.2009.08.012","article-title":"Caring for Machado-Joseph disease: current understanding and how to help patients","volume":"16","author":"D'Abreu","year":"2010","journal-title":"Parkinsonism Relat Disord. England"},{"key":"10.1007\/s13311-019-00798-1_bib13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12311-010-0183-8","article-title":"Neuropsychological features of patients with spinocerebellar ataxia (SCA) types 1, 2, 3, and 6","volume":"9","author":"Klinke","year":"2010","journal-title":"Cerebellum. United States"},{"key":"10.1007\/s13311-019-00798-1_bib14","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s12311-011-0340-8","article-title":"Pathoanatomy of cerebellar degeneration in spinocerebellar ataxia type 2 (SCA2) and type 3 (SCA3)","volume":"11","author":"Scherzed","year":"2012","journal-title":"Cerebellum. United States"},{"key":"10.1007\/s13311-019-00798-1_bib15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.410390411","article-title":"Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features","volume":"39","author":"Durr","year":"1996","journal-title":"Ann Neurol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/ana.410410408","article-title":"Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain","volume":"41","author":"Paulson","year":"1997","journal-title":"Ann Neurol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s004010000277","article-title":"Involvement of the cerebral cortex and autonomic ganglia in Machado-Joseph disease","volume":"101","author":"Yamada","year":"2001","journal-title":"Acta Neuropathol. Germany"},{"key":"10.1007\/s13311-019-00798-1_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(02)00110-7","article-title":"Intranuclear inclusions, neuronal loss and CAG mosaicism in two patients with Machado-Joseph disease","volume":"200","author":"Munoz","year":"2002","journal-title":"J Neurol Sci. Netherlands"},{"key":"10.1007\/s13311-019-00798-1_bib19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00401-007-0287-5","article-title":"CAG repeat disorder models and human neuropathology: similarities and differences","volume":"115","author":"Yamada","year":"2008","journal-title":"Acta Neuropathol. Germany"},{"key":"10.1007\/s13311-019-00798-1_bib20","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1093\/hmg\/ddn106","article-title":"Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease","volume":"17","author":"Alves","year":"2008","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archneur.55.1.33","article-title":"Characteristic magnetic resonance imaging findings in Machado-Joseph disease","volume":"55","author":"Murata","year":"1998","journal-title":"Arch Neurol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00004728-200303000-00023","article-title":"Magnetic resonance imaging findings of Machado-Joseph disease: histopathologic correlation","volume":"27","author":"Tokumaru","year":"2003","journal-title":"J Comput Assist Tomogr. United States"},{"key":"10.1007\/s13311-019-00798-1_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0896-6273(00)80943-5","article-title":"Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3","volume":"19","author":"Paulson","year":"1997","journal-title":"Neuron. United States"},{"key":"10.1007\/s13311-019-00798-1_bib24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1750-3639.1998.tb00193.x","article-title":"An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients","volume":"8","author":"Schmidt","year":"1998","journal-title":"Brain Pathol. Switzerland"},{"key":"10.1007\/s13311-019-00798-1_bib25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2990.2006.00772.x","article-title":"Degeneration of ingestion-related brainstem nuclei in spinocerebellar ataxia type 2, 3, 6 and 7","volume":"32","author":"Rub","year":"2006","journal-title":"Neuropathol Appl Neurobiol. England"},{"key":"10.1007\/s13311-019-00798-1_bib26","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1750-3639.2006.00022.x","article-title":"Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions","volume":"16","author":"Rub","year":"2006","journal-title":"Brain Pathol. Switzerland"},{"key":"10.1007\/s13311-019-00798-1_bib27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature. England"},{"key":"10.1007\/s13311-019-00798-1_bib28","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jmcb\/mjq005","article-title":"Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going?","volume":"2","author":"Takahashi","year":"2010","journal-title":"J Mol Cell Biol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1440-1819.2003.01102.x","article-title":"Immunohistochemical study of neuronal intranuclear and cytoplasmic inclusions in Machado-Joseph disease","volume":"57","author":"Hayashi","year":"2003","journal-title":"Psychiatry Clin Neurosci. Australia"},{"key":"10.1007\/s13311-019-00798-1_bib30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00401-010-0717-7","article-title":"Axonal inclusions in spinocerebellar ataxia type 3","volume":"120","author":"Seidel","year":"2010","journal-title":"Acta Neuropathol. Germany"},{"key":"10.1007\/s13311-019-00798-1_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-012-1000-x","article-title":"Brain pathology of spinocerebellar ataxias","volume":"124","author":"Seidel","year":"2012","journal-title":"Acta Neuropathol. Springer"},{"key":"10.1007\/s13311-019-00798-1_bib32","first-page":"916","article-title":"Adapting proteostasis for disease intervention","volume":"319","author":"Balch","year":"2008","journal-title":"Science. United States"},{"key":"10.1007\/s13311-019-00798-1_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1083\/jcb.201709072","article-title":"Pathways of cellular proteostasis in aging and disease","volume":"217","author":"Klaips","year":"2018","journal-title":"J Cell Biol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib34","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tcb.2014.05.003","article-title":"Proteostasis impairment in protein-misfolding and -aggregation diseases","volume":"24","author":"Hipp","year":"2014","journal-title":"Trends Cell Biol. England"},{"key":"10.1007\/s13311-019-00798-1_bib35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41580-019-0101-y","article-title":"The proteostasis network and its decline in ageing","volume":"20","author":"Hipp","year":"2019","journal-title":"Nat Rev Mol Cell Biol. England"},{"key":"10.1007\/s13311-019-00798-1_bib36","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1111\/j.1742-4658.2005.05021.x","article-title":"The Yin and Yang of protein folding","volume":"272","author":"Jahn","year":"2005","journal-title":"FEBS J. England"},{"key":"10.1007\/s13311-019-00798-1_bib37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/978-3-319-71779-1_14","article-title":"Polyglutamine-Independent Features in Ataxin-3 Aggregation and Pathogenesis of Machado-Joseph Disease","volume":"1049","author":"Carvalho","year":"2018","journal-title":"Adv Exp Med Biol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib38","doi-asserted-by":"crossref","first-page":"16888","DOI":"10.1074\/jbc.M601470200","article-title":"The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step","volume":"281","author":"Ellisdon","year":"2006","journal-title":"J Biol Chem. United States"},{"key":"10.1007\/s13311-019-00798-1_bib39","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jmb.2005.08.061","article-title":"Towards a structural understanding of the fibrillization pathway in Machado-Joseph's disease: trapping early oligomers of non-expanded ataxin-3","volume":"353","author":"Gales","year":"2005","journal-title":"J Mol Biol. England"},{"key":"10.1007\/s13311-019-00798-1_bib40","first-page":"11955","article-title":"An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel beta -fibrils. Proc Natl Acad Sci U S A","volume":"98","author":"Bevivino","year":"2001","journal-title":"United States"},{"key":"10.1007\/s13311-019-00798-1_bib41","first-page":"486","article-title":"Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis","volume":"300","author":"Kayed","year":"2003","journal-title":"Science. United States"},{"key":"10.1007\/s13311-019-00798-1_bib42","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1471-4159.2004.02369.x","article-title":"Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3","volume":"89","author":"Berke","year":"2004","journal-title":"J Neurochem. England"},{"key":"10.1007\/s13311-019-00798-1_bib43","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/hmg\/ddi472","article-title":"Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3","volume":"15","author":"Haacke","year":"2006","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib44","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1074\/jbc.M109.036335","article-title":"Nuclear aggregation of polyglutamine-expanded ataxin-3: fragments escape the cytoplasmic quality control","volume":"285","author":"Breuer","year":"2010","journal-title":"J Biol Chem. United States"},{"key":"10.1007\/s13311-019-00798-1_bib45","doi-asserted-by":"crossref","first-page":"9158","DOI":"10.1074\/jbc.273.15.9158","article-title":"Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract","volume":"273","author":"Wellington","year":"1998","journal-title":"J Biol Chem. United States"},{"key":"10.1007\/s13311-019-00798-1_bib46","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1093\/hmg\/ddp456","article-title":"Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3","volume":"18","author":"Jung","year":"2009","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib47","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/jnc.12684","article-title":"CDK5 protects from caspase-induced Ataxin-3 cleavage and neurodegeneration","volume":"129","author":"Liman","year":"2014","journal-title":"J Neurochem. England"},{"key":"10.1007\/s13311-019-00798-1_bib48","doi-asserted-by":"crossref","first-page":"18851","DOI":"10.1074\/jbc.M611914200","article-title":"Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3","volume":"282","author":"Haacke","year":"2007","journal-title":"J Biol Chem. United States"},{"key":"10.1007\/s13311-019-00798-1_bib49","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature10671","article-title":"Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease","volume":"480","author":"Koch","year":"2011","journal-title":"Nature. England"},{"key":"10.1007\/s13311-019-00798-1_bib50","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/hmg\/dds449","article-title":"Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3)","volume":"22","author":"Hubener","year":"2013","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib51","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-3-319-71779-1_18","article-title":"Molecular Mechanisms and Cellular Pathways Implicated in Machado-Joseph Disease Pathogenesis","volume":"1049","author":"Nobrega","year":"2018","journal-title":"Adv Exp Med Biol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib52","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/brain\/aws177","article-title":"Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease","volume":"135","author":"Simoes","year":"2012","journal-title":"Brain. England"},{"key":"10.1007\/s13311-019-00798-1_bib53","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/hmg\/8.4.673","article-title":"Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3\/MJD and suppression of polyglutamine aggregation in vitro","volume":"8","author":"Chai","year":"1999","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib54","doi-asserted-by":"crossref","first-page":"10338","DOI":"10.1523\/JNEUROSCI.19-23-10338.1999","article-title":"Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease","volume":"19","author":"Chai","year":"1999","journal-title":"J Neurosci. United States"},{"key":"10.1007\/s13311-019-00798-1_bib55","doi-asserted-by":"crossref","first-page":"44889","DOI":"10.1074\/jbc.M106575200","article-title":"The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease","volume":"276","author":"Chai","year":"2001","journal-title":"J Biol Chem. United States"},{"key":"10.1007\/s13311-019-00798-1_bib56","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ana.10101","article-title":"Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions","volume":"51","author":"Schmidt","year":"2002","journal-title":"Ann Neurol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib57","first-page":"8892","article-title":"Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates. Proc Natl Acad Sci U S A","volume":"100","author":"Donaldson","year":"2003","journal-title":"United States"},{"key":"10.1007\/s13311-019-00798-1_bib58","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1038\/srep06410","article-title":"Aggregation of polyglutamine-expanded ataxin-3 sequesters its specific interacting partners into inclusions: implication in a loss-of-function pathology","volume":"4","author":"Yang","year":"2014","journal-title":"Sci Rep. England"},{"key":"10.1007\/s13311-019-00798-1_bib59","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/ncb863","article-title":"Polyglutamine protein aggregates are dynamic","volume":"4","author":"Kim","year":"2002","journal-title":"Nat Cell Biol. England"},{"key":"10.1007\/s13311-019-00798-1_bib60","first-page":"67","article-title":"Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions","volume":"144","author":"Olzscha","year":"2011","journal-title":"Cell. United States"},{"key":"10.1007\/s13311-019-00798-1_bib61","first-page":"2232","article-title":"Disassembly of transcriptional regulatory complexes by molecular chaperones","volume":"296","author":"Freeman","year":"2002","journal-title":"Science. United States"},{"key":"10.1007\/s13311-019-00798-1_bib62","first-page":"26","article-title":"The role of molecular chaperones in clathrin mediated vesicular trafficking","volume":"2","author":"Sousa","year":"2015","journal-title":"Front Mol Biosci. Switzerland"},{"key":"10.1007\/s13311-019-00798-1_bib63","first-page":"468","article-title":"The Role of Heat Shock Proteins in Regulating Receptor Signal Transduction","volume":"95","author":"Streicher","year":"2019","journal-title":"Mol Pharmacol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib64","first-page":"E1481","article-title":"Protein aggregation can inhibit clathrin-mediated endocytosis by chaperone competition","volume":"111","author":"Yu","year":"2014","journal-title":"Proc Natl Acad Sci U S A. United States"},{"key":"10.1007\/s13311-019-00798-1_bib65","first-page":"134","article-title":"PolyQ proteins interfere with nuclear degradation of cytosolic proteins by sequestering the Sis1p chaperone","volume":"154","author":"Park","year":"2013","journal-title":"Cell. United States"},{"key":"10.1007\/s13311-019-00798-1_bib66","first-page":"1471","article-title":"Progressive disruption of cellular protein folding in models of polyglutamine diseases","volume":"311","author":"Gidalevitz","year":"2006","journal-title":"Science. United States"},{"key":"10.1007\/s13311-019-00798-1_bib67","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1128\/MCB.23.18.6469-6483.2003","article-title":"Ataxin-3 interactions with rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis","volume":"23","author":"Doss-Pepe","year":"2003","journal-title":"Mol Cell Biol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib68","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1093\/hmg\/ddg344","article-title":"The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity","volume":"12","author":"Burnett","year":"2003","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib69","doi-asserted-by":"crossref","first-page":"28576","DOI":"10.1074\/jbc.M111.299990","article-title":"Ataxin-3 regulates aggresome formation of copper-zinc superoxide dismutase (SOD1) by editing K63-linked polyubiquitin chains","volume":"287","author":"Wang","year":"2012","journal-title":"J Biol Chem. United States"},{"key":"10.1007\/s13311-019-00798-1_bib70","doi-asserted-by":"crossref","first-page":"e11728","DOI":"10.1371\/journal.pone.0011728","article-title":"Ataxin-3 plays a role in mouse myogenic differentiation through regulation of integrin subunit levels","volume":"5","author":"do Carmo Costa","year":"2010","journal-title":"PLoS One. United States"},{"key":"10.1007\/s13311-019-00798-1_bib71","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/hmg\/ddu422","article-title":"Dominant negative effect of polyglutamine expansion perturbs normal function of ataxin-3 in neuronal cells","volume":"24","author":"Neves-Carvalho","year":"2015","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib72","doi-asserted-by":"crossref","first-page":"e2000733","DOI":"10.1371\/journal.pbio.2000733","article-title":"The Machado-Joseph Disease Deubiquitinase Ataxin-3 Regulates the Stability and Apoptotic Function of p53","volume":"14","author":"Liu","year":"2016","journal-title":"PLoS Biol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib73","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1074\/jbc.M310939200","article-title":"Poly-ubiquitin Binding by the Polyglutamine Disease Protein Ataxin-3 Links Its Normal Function to Protein Surveillance Pathways","volume":"279","author":"Chai","year":"2004","journal-title":"J Biol Chem [Internet]."},{"key":"10.1007\/s13311-019-00798-1_bib74","first-page":"26436","article-title":"The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J Biol Chem","volume":"283","author":"Winborn","year":"2008","journal-title":"United States"},{"key":"10.1007\/s13311-019-00798-1_bib75","first-page":"2996","article-title":"Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways. Hum Mol Genet","volume":"20","author":"Teixeira-Castro","year":"2011","journal-title":"England"},{"key":"10.1007\/s13311-019-00798-1_bib76","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/hmg\/ddl164","article-title":"Ataxin-3 binds VCP\/p97 and regulates retrotranslocation of ERAD substrates","volume":"15","author":"Zhong","year":"2006","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib77","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/hmg\/ddq452","article-title":"The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability","volume":"20","author":"Durcan","year":"2011","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib78","first-page":"1552","article-title":"Impairment of the ubiquitin-proteasome system by protein aggregation","volume":"292","author":"Bence","year":"2001","journal-title":"Science. United States"},{"key":"10.1007\/s13311-019-00798-1_bib79","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.emboj.7600081","article-title":"Molecular clearance of ataxin-3 is regulated by a mammalian E4","volume":"23","author":"Matsumoto","year":"2004","journal-title":"EMBO J. England"},{"key":"10.1007\/s13311-019-00798-1_bib80","first-page":"22044","article-title":"Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem","volume":"278","author":"Tsai","year":"2003","journal-title":"United States"},{"key":"10.1007\/s13311-019-00798-1_bib81","doi-asserted-by":"crossref","first-page":"11635","DOI":"10.1074\/jbc.M412042200","article-title":"Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes","volume":"280","author":"Jana","year":"2005","journal-title":"J Biol Chem. United States"},{"key":"10.1007\/s13311-019-00798-1_bib82","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1038\/ncomms5638","article-title":"Ubiquitin-binding site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23","volume":"5","author":"Blount","year":"2014","journal-title":"Nat Commun. England"},{"key":"10.1007\/s13311-019-00798-1_bib83","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/hmg\/ddi458","article-title":"Rapamycin alleviates toxicity of different aggregate-prone proteins","volume":"15","author":"Berger","year":"2006","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib84","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/brain\/awp292","article-title":"Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3","volume":"133","author":"Menzies","year":"2010","journal-title":"Brain. England"},{"key":"10.1007\/s13311-019-00798-1_bib85","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature22078","article-title":"Polyglutamine tracts regulate beclin 1-dependent autophagy","volume":"545","author":"Ashkenazi","year":"2017","journal-title":"Nature. England"},{"key":"10.1007\/s13311-019-00798-1_bib86","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/brain\/awr047","article-title":"Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado\u2013Joseph disease.","volume":"134","author":"Nascimento-Ferreira","year":"2011","journal-title":"Brain [Internet]."},{"key":"10.1007\/s13311-019-00798-1_bib87","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/neup.12433","article-title":"Deregulation of autophagy in postmortem brains of Machado-Joseph disease patients","volume":"38","author":"Sittler","year":"2018","journal-title":"Neuropathology. Australia"},{"key":"10.1007\/s13311-019-00798-1_bib88","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s12311-014-0589-9","article-title":"Lithium chloride therapy fails to improve motor function in a transgenic mouse model of Machado-Joseph disease","volume":"13","author":"Duarte-Silva","year":"2014","journal-title":"Cerebellum. United States"},{"key":"10.1007\/s13311-019-00798-1_bib89","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/brain\/awt144","article-title":"Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease","volume":"136","author":"Nascimento-Ferreira","year":"2013","journal-title":"Brain. England"},{"key":"10.1007\/s13311-019-00798-1_bib90","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s13311-013-0255-9","article-title":"Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease","volume":"11","author":"Silva-Fernandes","year":"2014","journal-title":"Neurotherapeutics. United States"},{"key":"10.1007\/s13311-019-00798-1_bib91","doi-asserted-by":"crossref","first-page":"11445","DOI":"10.1038\/ncomms11445","article-title":"Caloric restriction blocks neuropathology and motor deficits in Machado-Joseph disease mouse models through SIRT1 pathway","volume":"7","author":"Cunha-Santos","year":"2016","journal-title":"Nat Commun. England"},{"key":"10.1007\/s13311-019-00798-1_bib92","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/hmg\/ddy328","article-title":"Cordycepin activates autophagy through AMPK phosphorylation to reduce abnormalities in Machado-Joseph disease models","volume":"28","author":"Marcelo","year":"2019","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib93","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-019-02019-7","article-title":"Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia.","author":"Nobrega","year":"2019","journal-title":"Acta Neuropathol. Germany;"},{"key":"10.1007\/s13311-019-00798-1_bib94","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12311-013-0516-5","article-title":"Mutant ataxin-3 with an abnormally expanded polyglutamine chain disrupts dendritic development and metabotropic glutamate receptor signaling in mouse cerebellar Purkinje cells","volume":"13","author":"Konno","year":"2014","journal-title":"Cerebellum. United States"},{"key":"10.1007\/s13311-019-00798-1_bib95","first-page":"162","article-title":"Combined therapy with m-TOR-dependent and -independent autophagy inducers causes neurotoxicity in a mouse model of Machado-Joseph disease","volume":"313","author":"Duarte-Silva","year":"2016","journal-title":"Neuroscience. United States"},{"key":"10.1007\/s13311-019-00798-1_bib96","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1073\/pnas.0407252102","article-title":"The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation","volume":"102","author":"Burnett","year":"2005","journal-title":"Proc Natl Acad Sci U S A. United States"},{"key":"10.1007\/s13311-019-00798-1_bib97","first-page":"47","article-title":"Aggresome formation and neurodegenerative diseases: therapeutic implications","volume":"15","author":"Olzmann","year":"2008","journal-title":"Curr Med Chem. United Arab Emirates"},{"key":"10.1007\/s13311-019-00798-1_bib98","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/hmg\/9.12.1795","article-title":"Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B","volume":"9","author":"Wang","year":"2000","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib99","first-page":"2923","article-title":"PolyQ-expanded huntingtin and ataxin-3 sequester ubiquitin adaptors hHR23B and UBQLN2 into aggregates via conjugated ubiquitin","volume":"32","author":"Yang","year":"2018","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nbd.2015.05.010","article-title":"The deubiquitinase ataxin-3 requires Rad23 and DnaJ-1 for its neuroprotective role in Drosophila melanogaster","volume":"82","author":"Tsou","year":"2015","journal-title":"Neurobiol Dis. United States"},{"key":"10.1007\/s13311-019-00798-1_bib101","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/hmg\/ddx039","article-title":"Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3","volume":"26","author":"Sutton","year":"2017","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib102","doi-asserted-by":"crossref","first-page":"e1004749","DOI":"10.1371\/journal.pgen.1004749","article-title":"The role of the mammalian DNA end-processing enzyme polynucleotide kinase 3'-phosphatase in spinocerebellar ataxia type 3 pathogenesis","volume":"11","author":"Chatterjee","year":"2015","journal-title":"PLoS Genet. United States"},{"key":"10.1007\/s13311-019-00798-1_bib103","doi-asserted-by":"crossref","first-page":"e1004834","DOI":"10.1371\/journal.pgen.1004834","article-title":"Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3","volume":"11","author":"Gao","year":"2015","journal-title":"PLoS Genet. United States"},{"key":"10.1007\/s13311-019-00798-1_bib104","doi-asserted-by":"crossref","first-page":"e1004937","DOI":"10.1371\/journal.pgen.1004937","article-title":"Ataxin-3, DNA damage repair, and SCA3 cerebellar degeneration: on the path to parsimony?","volume":"11","author":"Ward","year":"2015","journal-title":"PLoS Genet. United States"},{"key":"10.1007\/s13311-019-00798-1_bib105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuint.2010.11.005","article-title":"p53 activation mediates polyglutamine-expanded ataxin-3 upregulation of Bax expression in cerebellar and pontine nuclei neurons","volume":"58","author":"Chou","year":"2011","journal-title":"Neurochem Int. England"},{"key":"10.1007\/s13311-019-00798-1_bib106","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ajhg.2015.01.005","article-title":"Mutations in PNKP cause recessive ataxia with oculomotor apraxia type 4","volume":"96","author":"Bras","year":"2015","journal-title":"Am J Hum Genet. United States"},{"key":"10.1007\/s13311-019-00798-1_bib107","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s12311-016-0784-y","article-title":"PNKP Mutations Identified by Whole-Exome Sequencing in a Norwegian Patient with Sporadic Ataxia and Edema","volume":"16","author":"Tzoulis","year":"2017","journal-title":"Cerebellum. United States"},{"key":"10.1007\/s13311-019-00798-1_bib108","doi-asserted-by":"crossref","first-page":"R463","DOI":"10.1016\/j.cub.2014.03.033","article-title":"How the nucleus copes with proteotoxic stress","volume":"24","author":"Shibata","year":"2014","journal-title":"Curr Biol. England"},{"key":"10.1007\/s13311-019-00798-1_bib109","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ceb.2016.03.002","article-title":"Protein quality control in the nucleus","volume":"40","author":"Jones","year":"2016","journal-title":"Curr Opin Cell Biol. England"},{"key":"10.1007\/s13311-019-00798-1_bib110","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41586-018-0678-x","article-title":"Distinct proteostasis circuits cooperate in nuclear and cytoplasmic protein quality control","volume":"563","author":"Samant","year":"2018","journal-title":"Nature. England"},{"key":"10.1007\/s13311-019-00798-1_bib111","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1083\/jcb.143.6.1457","article-title":"Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation","volume":"143","author":"Perez","year":"1998","journal-title":"J Cell Biol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib112","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.1523\/JNEUROSCI.4540-06.2007","article-title":"Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence","volume":"27","author":"Bichelmeier","year":"2007","journal-title":"J Neurosci. United States"},{"key":"10.1007\/s13311-019-00798-1_bib113","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/hmg\/9.14.2197","article-title":"CREB-binding protein sequestration by expanded polyglutamine","volume":"9","author":"McCampbell","year":"2000","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib114","doi-asserted-by":"crossref","first-page":"45004","DOI":"10.1074\/jbc.M205259200","article-title":"Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities","volume":"277","author":"Li","year":"2002","journal-title":"J Biol Chem. United States"},{"key":"10.1007\/s13311-019-00798-1_bib115","doi-asserted-by":"crossref","first-page":"11474","DOI":"10.1523\/JNEUROSCI.2053-06.2006","article-title":"Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation","volume":"26","author":"Evert","year":"2006","journal-title":"J Neurosci. United States"},{"key":"10.1007\/s13311-019-00798-1_bib116","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1093\/hmg\/ddr197","article-title":"FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3","volume":"20","author":"Araujo","year":"2011","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib117","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.nbd.2008.03.011","article-title":"Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation","volume":"31","author":"Chou","year":"2008","journal-title":"Neurobiol Dis. United States"},{"key":"10.1007\/s13311-019-00798-1_bib118","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nbd.2010.10.019","article-title":"HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3","volume":"41","author":"Chou","year":"2011","journal-title":"Neurobiol Dis. United States"},{"key":"10.1007\/s13311-019-00798-1_bib119","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.brainres.2014.08.019","article-title":"Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation","volume":"1583","author":"Chou","year":"2014","journal-title":"Brain Res. Netherlands"},{"key":"10.1007\/s13311-019-00798-1_bib120","doi-asserted-by":"crossref","first-page":"e0141610","DOI":"10.1371\/journal.pone.0141610","article-title":"Limited Effect of Chronic Valproic Acid Treatment in a Mouse Model of Machado-Joseph Disease","volume":"10","author":"Esteves","year":"2015","journal-title":"PLoS One. United States"},{"key":"10.1007\/s13311-019-00798-1_bib121","doi-asserted-by":"crossref","DOI":"10.1007\/s12035-019-01643-4","article-title":"Altered Levels of Proteins and Phosphoproteins, in the Absence of Early Causative Transcriptional Changes, Shape the Molecular Pathogenesis in the Brain of Young Presymptomatic Ki91 SCA3\/MJD Mouse.","author":"Wiatr","year":"2019","journal-title":"Mol Neurobiol. United States;"},{"key":"10.1007\/s13311-019-00798-1_bib122","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13024-018-0261-9","article-title":"Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model","volume":"13","author":"Toonen","year":"2018","journal-title":"Mol Neurodegener. England"},{"key":"10.1007\/s13311-019-00798-1_bib123","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/sj.cdd.4402219","article-title":"Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation","volume":"14","author":"Li","year":"2007","journal-title":"Cell Death Differ. England"},{"key":"10.1007\/s13311-019-00798-1_bib124","doi-asserted-by":"crossref","first-page":"e54792","DOI":"10.1371\/journal.pone.0054792","article-title":"Sodium valproate alleviates neurodegeneration in SCA3\/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4","volume":"8","author":"Yi","year":"2013","journal-title":"PLoS One. United States"},{"key":"10.1007\/s13311-019-00798-1_bib125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijdevneu.2014.07.004","article-title":"Valproic acid attenuates the suppression of acetyl histone H3 and CREB activity in an inducible cell model of Machado-Joseph disease","volume":"38","author":"Lin","year":"2014","journal-title":"Int J Dev Neurosci. England"},{"key":"10.1007\/s13311-019-00798-1_bib126","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/cns.12795","article-title":"Divalproex sodium modulates nuclear localization of ataxin-3 and prevents cellular toxicity caused by expanded ataxin-3","volume":"24","author":"Wang","year":"2018","journal-title":"CNS Neurosci Ther. England"},{"key":"10.1007\/s13311-019-00798-1_bib127","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.ymthe.2017.01.021","article-title":"Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease","volume":"25","author":"Carmona","year":"2017","journal-title":"Mol Ther. United States"},{"key":"10.1007\/s13311-019-00798-1_bib128","doi-asserted-by":"crossref","first-page":"e0201794","DOI":"10.1371\/journal.pone.0201794","article-title":"Upregulation of miR-370 and miR-543 is associated with reduced expression of heat shock protein 40 in spinocerebellar ataxia type 3","volume":"13","author":"Evert","year":"2018","journal-title":"PLoS One. United States"},{"key":"10.1007\/s13311-019-00798-1_bib129","first-page":"76","article-title":"Upregulation of miR-25 and miR-181 Family Members Correlates with Reduced Expression of ATXN3 in Lymphocytes from SCA3 Patients. MicroRNA (Shariqah, United Arab Emirates)","volume":"8","author":"Krauss","year":"2019","journal-title":"United Arab Emirates"},{"key":"10.1007\/s13311-019-00798-1_bib130","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bbrc.2007.03.160","article-title":"Phosphorylation of ataxin-3 by glycogen synthase kinase 3beta at serine 256 regulates the aggregation of ataxin-3","volume":"357","author":"Fei","year":"2007","journal-title":"Biochem Biophys Res Commun. United States"},{"key":"10.1007\/s13311-019-00798-1_bib131","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1093\/hmg\/ddp274","article-title":"CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3","volume":"18","author":"Mueller","year":"2009","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib132","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1083\/jcb.201506025","article-title":"Ataxin-3 phosphorylation decreases neuronal defects in spinocerebellar ataxia type 3 models","volume":"212","author":"Matos","year":"2016","journal-title":"J Cell Biol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib133","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/emboj.2008.289","article-title":"Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin-3","volume":"28","author":"Todi","year":"2009","journal-title":"EMBO J. England"},{"key":"10.1007\/s13311-019-00798-1_bib134","doi-asserted-by":"crossref","first-page":"39303","DOI":"10.1074\/jbc.M110.181610","article-title":"Activity and cellular functions of the deubiquitinating enzyme and polyglutamine disease protein ataxin-3 are regulated by ubiquitination at lysine 117","volume":"285","author":"Todi","year":"2010","journal-title":"J Biol Chem. United States"},{"key":"10.1007\/s13311-019-00798-1_bib135","first-page":"34460","article-title":"Ubiquitination regulates the neuroprotective function of the deubiquitinase ataxin-3 in vivo. J Biol Chem","volume":"288","author":"Tsou","year":"2013","journal-title":"United States"},{"key":"10.1007\/s13311-019-00798-1_bib136","doi-asserted-by":"crossref","first-page":"e54214","DOI":"10.1371\/journal.pone.0054214","article-title":"SUMO-1 modification on K166 of polyQ-expanded ataxin-3 strengthens its stability and increases its cytotoxicity","volume":"8","author":"Zhou","year":"2013","journal-title":"PLoS One. United States"},{"key":"10.1007\/s13311-019-00798-1_bib137","first-page":"1950","article-title":"SUMOylation of the brain-predominant Ataxin-3 isoform modulates its interaction with p97","volume":"2015","author":"Almeida","year":"1852","journal-title":"Biochim Biophys Acta. Netherlands"},{"key":"10.1007\/s13311-019-00798-1_bib138","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.nbd.2008.01.011","article-title":"Study of subcellular localization and proteolysis of ataxin-3","volume":"30","author":"Pozzi","year":"2008","journal-title":"Neurobiol Dis. United States"},{"key":"10.1007\/s13311-019-00798-1_bib139","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.neuint.2017.10.013","article-title":"Mass spectrometry analyses of normal and polyglutamine expanded ataxin-3 reveal novel interaction partners involved in mitochondrial function","volume":"112","author":"Kristensen","year":"2018","journal-title":"Neurochem Int. England"},{"key":"10.1007\/s13311-019-00798-1_bib140","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-0404.1996.tb00174.x","article-title":"Elevated cerebrospinal fluid lactate\/pyruvate ratio in Machado-Joseph disease","volume":"93","author":"Matsuishi","year":"1996","journal-title":"Acta Neurol Scand. Denmark"},{"key":"10.1007\/s13311-019-00798-1_bib141","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.bbrc.2004.09.192","article-title":"Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells","volume":"324","author":"Tsai","year":"2004","journal-title":"Biochem Biophys Res Commun. United States"},{"key":"10.1007\/s13311-019-00798-1_bib142","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.nbd.2005.07.011","article-title":"Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL","volume":"21","author":"Chou","year":"2006","journal-title":"Neurobiol Dis. United States"},{"key":"10.1007\/s13311-019-00798-1_bib143","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/jnr.22011","article-title":"Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease","volume":"87","author":"Yu","year":"2009","journal-title":"J Neurosci Res. United States"},{"key":"10.1007\/s13311-019-00798-1_bib144","first-page":"139","article-title":"Compromised mitochondrial complex II in models of Machado-Joseph disease","volume":"2012","author":"Laco","year":"1822","journal-title":"Biochim Biophys Acta. Netherlands"},{"key":"10.1007\/s13311-019-00798-1_bib145","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000339207","article-title":"Patterns of mitochondrial DNA damage in blood and brain tissues of a transgenic mouse model of Machado-Joseph disease","volume":"11","author":"Kazachkova","year":"2013","journal-title":"Neurodegener Dis. Switzerland"},{"key":"10.1007\/s13311-019-00798-1_bib146","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12031-014-0360-1","article-title":"Differential mtDNA damage patterns in a transgenic mouse model of Machado-Joseph disease (MJD\/SCA3)","volume":"55","author":"Ramos","year":"2015","journal-title":"J Mol Neurosci. United States"},{"key":"10.1007\/s13311-019-00798-1_bib147","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fnmol.2018.00368","article-title":"Mitochondrial Morphology, Function and Homeostasis Are Impaired by Expression of an N-terminal Calpain Cleavage Fragment of Ataxin-3","volume":"11","author":"Harmuth","year":"2018","journal-title":"Front Mol Neurosci. Switzerland"},{"key":"10.1007\/s13311-019-00798-1_bib148","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/mds.27292","article-title":"Neuroprotective Effects of Creatine in the CMVMJD135 Mouse Model of Spinocerebellar Ataxia Type 3","volume":"33","author":"Duarte-Silva","year":"2018","journal-title":"Mov Disord. United States"},{"key":"10.1007\/s13311-019-00798-1_bib149","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/brain\/awr118","article-title":"N-terminal ataxin-3 causes neurological symptoms with inclusions, endoplasmic reticulum stress and ribosomal dislocation","volume":"134","author":"Hubener","year":"2011","journal-title":"Brain. England"},{"key":"10.1007\/s13311-019-00798-1_bib150","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0955-0674(02)00358-7","article-title":"ER-associated degradation in protein quality control and cellular regulation","volume":"14","author":"Hampton","year":"2002","journal-title":"Curr Opin Cell Biol. England"},{"key":"10.1007\/s13311-019-00798-1_bib151","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1093\/emboj\/cdg227","article-title":"For whom the bell tolls: protein quality control of the endoplasmic reticulum and the ubiquitin-proteasome connection","volume":"22","author":"Kostova","year":"2003","journal-title":"EMBO J. England"},{"key":"10.1007\/s13311-019-00798-1_bib152","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/bies.10320","article-title":"Evolving questions and paradigm shifts in endoplasmic-reticulum-associated degradation (ERAD)","volume":"25","author":"McCracken","year":"2003","journal-title":"Bioessays. United States"},{"key":"10.1007\/s13311-019-00798-1_bib153","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/414652a","article-title":"The AAA ATPase Cdc48\/p97 and its partners transport proteins from the ER into the cytosol","volume":"414","author":"Ye","year":"2001","journal-title":"Nature. England"},{"key":"10.1007\/s13311-019-00798-1_bib154","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ncb746","article-title":"Protein dislocation from the ER requires polyubiquitination and the AAA-ATPase Cdc48","volume":"4","author":"Jarosch","year":"2002","journal-title":"Nat Cell Biol. England"},{"key":"10.1007\/s13311-019-00798-1_bib155","first-page":"435","article-title":"Endoplasmic reticulum-associated degradation. Annu Rev Cell Dev Biol","volume":"21","author":"Romisch","year":"2005","journal-title":"United States"},{"key":"10.1007\/s13311-019-00798-1_bib156","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/sj.emboj.7601043","article-title":"An arginine\/lysine-rich motif is crucial for VCP\/p97-mediated modulation of ataxin-3 fibrillogenesis","volume":"25","author":"Boeddrich","year":"2006","journal-title":"EMBO J. England"},{"key":"10.1007\/s13311-019-00798-1_bib157","first-page":"1465","article-title":"Rescue of ATXN3 neuronal toxicity in Caenorhabditiselegans by chemical modification of endoplasmic reticulum stress","volume":"10","author":"Fardghassemi","year":"2017","journal-title":"Dis Model Mech. England"},{"key":"10.1007\/s13311-019-00798-1_bib158","doi-asserted-by":"crossref","first-page":"12713","DOI":"10.1523\/JNEUROSCI.3909-08.2008","article-title":"Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3","volume":"28","author":"Chen","year":"2008","journal-title":"J Neurosci. United States"},{"key":"10.1007\/s13311-019-00798-1_bib159","first-page":"3155","article-title":"Different ataxin-3 amyloid aggregates induce intracellular Ca(2+) deregulation by different mechanisms in cerebellar granule cells","volume":"2013","author":"Pellistri","year":"1833","journal-title":"Biochim Biophys Acta. Netherlands"},{"key":"10.1007\/s13311-019-00798-1_bib160","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ceca.2011.03.003","article-title":"Calcium and cell death mechanisms: a perspective from the cell death community","volume":"50","author":"Zhivotovsky","year":"2011","journal-title":"Cell Calcium. Netherlands"},{"key":"10.1007\/s13311-019-00798-1_bib161","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/jnnp.66.2.222","article-title":"Age related axonal neuropathy in spinocerebellar ataxia type 3\/Machado-Joseph disease (SCA3\/MJD)","volume":"66","author":"Klockgether","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry. England"},{"key":"10.1007\/s13311-019-00798-1_bib162","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1552-6569.2008.00260.x","article-title":"Axonal dysfunction in the deep white matter in Machado-Joseph disease","volume":"19","author":"D'Abreu","year":"2009","journal-title":"J Neuroimaging. United States"},{"key":"10.1007\/s13311-019-00798-1_bib163","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1471-4159.2006.03895.x","article-title":"Expanded polyglutamines impair synaptic transmission and ubiquitin-proteasome system in Caenorhabditis elegans","volume":"98","author":"Khan","year":"2006","journal-title":"J Neurochem. England"},{"key":"10.1007\/s13311-019-00798-1_bib164","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1093\/brain\/awv262","article-title":"Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease","volume":"138","author":"Teixeira-Castro","year":"2015","journal-title":"Brain. England"},{"key":"10.1007\/s13311-019-00798-1_bib165","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/brain\/aww228","article-title":"Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3","volume":"139","author":"Costa","year":"2016","journal-title":"Brain. England"},{"key":"10.1007\/s13311-019-00798-1_bib166","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jgg.2012.04.009","article-title":"Automated behavioral phenotyping reveals presymptomatic alterations in a SCA3 genetrap mouse model","volume":"39","author":"Hubener","year":"2012","journal-title":"J Genet Genomics. China"},{"key":"10.1007\/s13311-019-00798-1_bib167","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ana.25297","article-title":"Structural signature of SCA3: From presymptomatic to late disease stages","volume":"84","author":"Rezende","year":"2018","journal-title":"Ann Neurol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib168","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.neuropharm.2017.02.014","article-title":"n-Butylidenephthalide exhibits protection against neurotoxicity through regulation of tryptophan 2, 3 dioxygenase in spinocerebellar ataxia type 3","volume":"117","author":"Rajamani","year":"2017","journal-title":"Neuropharmacology. England"},{"key":"10.1007\/s13311-019-00798-1_bib169","first-page":"407","article-title":"Pereira de Almeida L. Caffeine alleviates progressive motor deficits in a transgenic mouse model of spinocerebellar ataxia. Ann Neurol","volume":"81","author":"Goncalves","year":"2017","journal-title":"United States"},{"key":"10.1007\/s13311-019-00798-1_bib170","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1007\/s12035-018-1332-1","article-title":"Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease","volume":"56","author":"Esteves","year":"2019","journal-title":"Mol Neurobiol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib171","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1007\/s12035-018-1331-2","article-title":"Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease","volume":"56","author":"Ashraf","year":"2019","journal-title":"Mol Neurobiol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib172","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2013.01.006","article-title":"H1152 promotes the degradation of polyglutamine-expanded ataxin-3 or ataxin-7 independently of its ROCK-inhibiting effect and ameliorates mutant ataxin-3-induced neurodegeneration in the SCA3 transgenic mouse","volume":"70","author":"Wang","year":"2013","journal-title":"Neuropharmacology. England"},{"key":"10.1007\/s13311-019-00798-1_bib173","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuropharm.2015.08.009","article-title":"T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse","volume":"99","author":"Chou","year":"2015","journal-title":"Neuropharmacology. England"},{"key":"10.1007\/s13311-019-00798-1_bib174","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/978-3-319-71779-1_19","article-title":"Pharmacological Therapies for Machado-Joseph Disease","volume":"1049","author":"Duarte-Silva","year":"2018","journal-title":"Adv Exp Med Biol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib175","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/mds.25803","article-title":"A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease","volume":"29","author":"Saute","year":"2014","journal-title":"Mov Disord. United States"},{"key":"10.1007\/s13311-019-00798-1_bib176","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/jnc.13606","article-title":"In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3","volume":"138","author":"Schmidt","year":"2016","journal-title":"J Neurochem. England"},{"key":"10.1007\/s13311-019-00798-1_bib177","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-019-0074-3","article-title":"Spinocerebellar ataxia","volume":"5","author":"Klockgether","year":"2019","journal-title":"Nat Rev Dis Prim. England"},{"key":"10.1007\/s13311-019-00798-1_bib178","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/jnc.14541","article-title":"Machado-Joseph disease\/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy","volume":"148","author":"Matos","year":"2019","journal-title":"J Neurochem. England"},{"key":"10.1007\/s13311-019-00798-1_bib179","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13023-019-1013-9","article-title":"Guidelines on the diagnosis and management of the progressive ataxias","volume":"14","author":"de Silva","year":"2019","journal-title":"Orphanet J Rare Dis. England"},{"key":"10.1007\/s13311-019-00798-1_bib180","unstructured":"Council NH and MR. NHMRC additional levels of evidence and grades for recommendations for developers of guidelines. NHMRC. NHMRC Canberra, Australia; 2009"},{"key":"10.1007\/s13311-019-00798-1_bib181","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/ene.12341","article-title":"EFNS\/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood","volume":"21","author":"van de Warrenburg","year":"2014","journal-title":"Eur J Neurol. England"},{"key":"10.1007\/s13311-019-00798-1_bib182","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1212\/WNL.0b013e318247cc7a","article-title":"A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3","volume":"78","author":"Zesiewicz","year":"2012","journal-title":"Neurology. United States"},{"key":"10.1007\/s13311-019-00798-1_bib183","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/B978-0-444-51892-7.00027-9","article-title":"Machado-Joseph Disease\/Spinocerebellar Ataxia Type 3","volume":"103","author":"Paulson","year":"2012","journal-title":"Handb Clin Neurol \/ Ed by PJ Vinken GW Bruyn."},{"key":"10.1007\/s13311-019-00798-1_bib184","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12311-008-0013-4","article-title":"SCA3: Neurological features, pathogenesis and animal models.","volume":"7","author":"Riess","year":"2008","journal-title":"The Cerebellum [Internet]."},{"key":"10.1007\/s13311-019-00798-1_bib185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0022-510X(95)00296-E","article-title":"Tetrahydrobiopterin double-blind, crossover trial in Machado-Joseph disease.","volume":"136","author":"Sakai","year":"1996","journal-title":"J Neurol Sci [Internet]. Elsevier;"},{"key":"10.1007\/s13311-019-00798-1_bib186","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1054\/mehy.2001.1293","article-title":"Effects of tetrahydrobiopterin on ataxia in Machado-Joseph disease may be based upon the theory of \u201ccerebellar long-term depression\u201d","volume":"57","author":"Sakai","year":"2001","journal-title":"Med Hypotheses. United States"},{"key":"10.1007\/s13311-019-00798-1_bib187","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1212\/WNL.0b013e3181d31e23","article-title":"Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial","volume":"74","author":"Ristori","year":"2010","journal-title":"Neurology. United States"},{"key":"10.1007\/s13311-019-00798-1_bib188","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S1474-4422(15)00201-X","article-title":"Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Romano","year":"2015","journal-title":"Lancet Neurol. England"},{"key":"10.1007\/s13311-019-00798-1_bib189","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00002826-200401000-00005","article-title":"Effects of tandospirone on \u201c5-HT1A receptor-associated symptoms\u201d in patients with Machado-Josephe disease: an open-label study","volume":"27","author":"Takei","year":"2004","journal-title":"Clin Neuropharmacol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib190","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s12311-010-0199-0","article-title":"Difference in the effects of tandospirone on ataxia in various types of spinocerebellar degeneration: an open-label study","volume":"9","author":"Takei","year":"2010","journal-title":"Cerebellum. United States"},{"issue":"13","key":"10.1007\/s13311-019-00798-1_bib191","article-title":"IGF-1 in autosomal dominant cerebellar ataxia - open-label trial.","volume":"1","author":"Sanz-Gallego","year":"2014","journal-title":"Cerebellum & ataxias. England;"},{"key":"10.1007\/s13311-019-00798-1_bib192","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/archneur.58.9.1451","article-title":"Double-blind crossover trial of trimethoprim-sulfamethoxazole in spinocerebellar ataxia type 3\/Machado-Joseph disease","volume":"58","author":"Schulte","year":"2001","journal-title":"Arch Neurol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib193","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1034\/j.1600-0404.2003.02132.x","article-title":"Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study","volume":"107","author":"Monte","year":"2003","journal-title":"Acta Neurol Scand. Denmark"},{"key":"10.1007\/s13311-019-00798-1_bib194","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1600-0404.2005.00405.x","article-title":"Clinical and molecular events in patients with Machado-Joseph disease under lamotrigine therapy","volume":"111","author":"Liu","year":"2005","journal-title":"Acta Neurol Scand. Denmark"},{"key":"10.1007\/s13311-019-00798-1_bib195","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1055\/s-0036-1571847","article-title":"Botulinum Toxin Treatment of Spasticity in Adults and Children","volume":"36","author":"Moeini-Naghani","year":"2016","journal-title":"Semin Neurol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib196","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/sc.2014.241","article-title":"Chemodenervation for treatment of limb spasticity following spinal cord injury: a systematic review","volume":"53","author":"Lui","year":"2015","journal-title":"Spinal Cord. England"},{"key":"10.1007\/s13311-019-00798-1_bib197","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000497165","article-title":"Inherited Ataxia and Intrathecal Baclofen for the Treatment of Spasticity and Painful Spasms","volume":"97","author":"Berntsson","year":"2019","journal-title":"Stereotact Funct Neurosurg. Switzerland"},{"key":"10.1007\/s13311-019-00798-1_bib198","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1212\/WNL.0b013e3181cbcd2f","article-title":"Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child","volume":"74","author":"Delgado","year":"2010","journal-title":"Neurology. United States"},{"key":"10.1007\/s13311-019-00798-1_bib199","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1177\/1352458516643600","article-title":"Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper","volume":"22","author":"Otero-Romero","year":"2016","journal-title":"Mult Scler. England"},{"key":"10.1007\/s13311-019-00798-1_bib200","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1212\/WNL.36.2.160","article-title":"Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl","volume":"36","author":"Burke","year":"1986","journal-title":"Neurology. United States"},{"key":"10.1007\/s13311-019-00798-1_bib201","first-page":"199","article-title":"Intrathecal baclofen in the treatment of dystonia","volume":"78","author":"Ford","year":"1998","journal-title":"Adv Neurol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib202","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.410110108","article-title":"Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study","volume":"11","author":"Jankovic","year":"1982","journal-title":"Ann Neurol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1353-8020(00)00084-5","article-title":"The long-term response to levodopa in dopa-responsive dystonia","volume":"8","author":"Hwang","year":"2001","journal-title":"Parkinsonism Relat Disord. England"},{"key":"10.1007\/s13311-019-00798-1_bib204","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology. United States"},{"key":"10.1007\/s13311-019-00798-1_bib205","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/brain\/awg073","article-title":"Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment","volume":"126","author":"Kanai","year":"2003","journal-title":"Brain. England"},{"key":"10.1007\/s13311-019-00798-1_bib206","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1007\/s00415-015-7659-x","article-title":"Neurogenic muscle cramps","volume":"262","author":"Katzberg","year":"2015","journal-title":"J Neurol. Germany"},{"key":"10.1007\/s13311-019-00798-1_bib207","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ana.410380422","article-title":"Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion","volume":"38","author":"Tuite","year":"1995","journal-title":"Ann Neurol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib208","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/pgmj.2003.015297","article-title":"Dramatic levodopa responsiveness of dystonia in a sporadic case of spinocerebellar ataxia type 3","volume":"80","author":"Nandagopal","year":"2004","journal-title":"Postgrad Med J. England"},{"key":"10.1007\/s13311-019-00798-1_bib209","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jnnp.71.1.107","article-title":"Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis?","volume":"71","author":"Bandini","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry. England"},{"key":"10.1007\/s13311-019-00798-1_bib210","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ana.410410620","article-title":"A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus","volume":"41","author":"Averbuch-Heller","year":"1997","journal-title":"Ann Neurol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib211","first-page":"295","article-title":"Pharmacological agents affecting emesis. A review (Part I). Drugs","volume":"43","author":"Mitchelson","year":"1992","journal-title":"New Zealand"},{"key":"10.1007\/s13311-019-00798-1_bib212","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.anorl.2011.10.006","article-title":"A protective effect of 5-HT3 antagonist against vestibular deficit? Metoclopramide versus ondansetron at the early stage of vestibular neuritis: a pilot study","volume":"129","author":"Venail","year":"2012","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis. France"},{"key":"10.1007\/s13311-019-00798-1_bib213","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/VES-130494","article-title":"Neuropharmacological basis of vestibular system disorder treatment","volume":"23","author":"Soto","year":"2013","journal-title":"J Vestib Res. Netherlands"},{"key":"10.1007\/s13311-019-00798-1_bib214","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00002508-200103000-00005","article-title":"Pharmacologic pain treatment of musculoskeletal disorders: current perspectives and future prospects","volume":"17","author":"Curatolo","year":"2001","journal-title":"Clin J Pain. United States"},{"key":"10.1007\/s13311-019-00798-1_bib215","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.mayocp.2015.01.018","article-title":"Neuropathic pain: principles of diagnosis and treatment","volume":"90","author":"Gilron","year":"2015","journal-title":"Mayo Clin Proc. England"},{"key":"10.1007\/s13311-019-00798-1_bib216","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/nau.22764","article-title":"A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders","volume":"35","author":"Sakakibara","year":"2016","journal-title":"Neurourol Urodyn. United States"},{"key":"10.1007\/s13311-019-00798-1_bib217","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1532-5415.2009.02220.x","article-title":"Evidence-based recommendations for the assessment and management of sleep disorders in older persons","volume":"57","author":"Bloom","year":"2009","journal-title":"J Am Geriatr Soc. United States"},{"key":"10.1007\/s13311-019-00798-1_bib218","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","article-title":"Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin","volume":"30","author":"Morgenthaler","year":"2007","journal-title":"Sleep. United States"},{"key":"10.1007\/s13311-019-00798-1_bib219","first-page":"19","article-title":"Depressive symptoms in Machado-Joseph disease (SCA3) patients and their relatives","volume":"10","author":"Cecchin","year":"2007","journal-title":"Community Genet. Switzerland"},{"key":"10.1007\/s13311-019-00798-1_bib220","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1212\/WNL.0b013e3181c33adf","article-title":"Intensive coordinative training improves motor performance in degenerative cerebellar disease","volume":"73","author":"Ilg","year":"2009","journal-title":"Neurology. United States"},{"key":"10.1007\/s13311-019-00798-1_bib221","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/1545968311425918","article-title":"Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases","volume":"26","author":"Miyai","year":"2012","journal-title":"Neurorehabil Neural Repair. United States"},{"key":"10.1007\/s13311-019-00798-1_bib222","doi-asserted-by":"crossref","first-page":"7816","DOI":"10.1038\/s41598-018-26109-w","article-title":"A randomized controlled pilot trial of game-based training in individuals with spinocerebellar ataxia type 3","volume":"8","author":"Wang","year":"2018","journal-title":"Sci Rep. England"},{"key":"10.1007\/s13311-019-00798-1_bib223","first-page":"582","article-title":"Understanding the Lived Experience of Five Individuals with Mobility Aids","volume":"229","author":"Walsh","year":"2016","journal-title":"Stud Health Technol Inform. Netherlands"},{"key":"10.1007\/s13311-019-00798-1_bib224","first-page":"277","article-title":"Principles of motor learning in treatment of motor speech disorders. Am J speech-language Pathol","volume":"17","author":"Maas","year":"2008","journal-title":"United States"},{"key":"10.1007\/s13311-019-00798-1_bib225","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008953.pub2","article-title":"Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes.","author":"Vogel","year":"2014","journal-title":"Cochrane database Syst Rev. England;"},{"key":"10.1007\/s13311-019-00798-1_bib226","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/bs.afnr.2016.11.008","article-title":"Nutritional Aspects of Dysphagia Management","volume":"81","author":"Gallegos","year":"2017","journal-title":"Adv Food Nutr Res. United States"},{"key":"10.1007\/s13311-019-00798-1_bib227","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1590\/S0100-879X2010005000009","article-title":"Occupational therapy in spinocerebellar ataxia type 3: an open-label trial","volume":"43","author":"Silva","year":"2010","journal-title":"Brazilian J Med Biol Res = Rev Bras Pesqui medicas e Biol. Brazil"},{"key":"10.1007\/s13311-019-00798-1_bib228","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00415-013-6910-6","article-title":"The effectiveness of allied health care in patients with ataxia: a systematic review","volume":"261","author":"Fonteyn","year":"2014","journal-title":"J Neurol. Germany"},{"key":"10.1007\/s13311-019-00798-1_bib229","first-page":"355","article-title":"Multidisciplinary Procedures for Designing Housing Adaptations for People with Mobility Disabilities","volume":"229","author":"Sukkay","year":"2016","journal-title":"Stud Health Technol Inform. Netherlands"},{"key":"10.1007\/s13311-019-00798-1_bib230","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mds.10192","article-title":"Chronic thalamic stimulation in a patient with spinocerebellar ataxia type 2","volume":"18","author":"Pirker","year":"2003","journal-title":"Mov Disord. United States"},{"key":"10.1007\/s13311-019-00798-1_bib231","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/mds.22758","article-title":"Deep brain stimulation in the posterior subthalamic area in the treatment of essential tremor","volume":"25","author":"Blomstedt","year":"2010","journal-title":"Mov Disord. United States"},{"key":"10.1007\/s13311-019-00798-1_bib232","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MOP.0000000000000567","article-title":"Management of hypertonia in cerebral palsy","volume":"30","author":"Nahm","year":"2018","journal-title":"Curr Opin Pediatr. United States"},{"key":"10.1007\/s13311-019-00798-1_bib233","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00455-016-9717-7","article-title":"Outcome of Rehabilitation and Swallowing Therapy after Percutaneous Endoscopic Gastrostomy in Dysphagia Patients","volume":"31","author":"Toh Yoon","year":"2016","journal-title":"Dysphagia. United States"},{"key":"10.1007\/s13311-019-00798-1_bib234","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/978-3-319-71779-1_17","article-title":"Planning Future Clinical Trials for Machado-Joseph Disease","volume":"1049","author":"Saute","year":"2018","journal-title":"Adv Exp Med Biol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib235","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.parkreldis.2016.03.005","article-title":"Safety and efficacy of valproic acid treatment in SCA3\/MJD patients","volume":"26","author":"Lei","year":"2016","journal-title":"Parkinsonism Relat Disord. England"},{"key":"10.1007\/s13311-019-00798-1_bib236","first-page":"351","article-title":"Novel Lactulose and Melibiose Targeting Autophagy to Reduce PolyQ Aggregation in Cell Models of Spinocerebellar Ataxia 3. CNS Neurol Disord Drug Targets","volume":"15","author":"Lin","year":"2016","journal-title":"United Arab Emirates"},{"key":"10.1007\/s13311-019-00798-1_bib237","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/ajmg.a.38413","article-title":"Challenges of developing and conducting clinical trials in rare disorders","volume":"176","author":"Kempf","year":"2018","journal-title":"Am J Med Genet A. United States"},{"key":"10.1007\/s13311-019-00798-1_bib238","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-3-319-67144-4_10","article-title":"Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs","volume":"1031","author":"Le","year":"2017","journal-title":"Adv Exp Med Biol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib239","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","article-title":"Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group","volume":"18","author":"Richter","year":"2015","journal-title":"Value Heal J Int Soc Pharmacoeconomics Outcomes Res. United States"},{"key":"10.1007\/s13311-019-00798-1_bib240","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000358801","article-title":"The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies","volume":"42","author":"Ruano","year":"2014","journal-title":"Neuroepidemiology. Switzerland"},{"key":"10.1007\/s13311-019-00798-1_bib241","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cpt.426","article-title":"History of Orphan Drug Regulation-United States and Beyond","volume":"100","author":"Haffner","year":"2016","journal-title":"Clin Pharmacol Ther. United States"},{"key":"10.1007\/s13311-019-00798-1_bib242","first-page":"341","article-title":"European regulation on orphan medicinal products: 10 years of experience and future perspectives","author":"Westermark","year":"2011","journal-title":"Nat. Rev. Drug Discov. England;"},{"key":"10.1007\/s13311-019-00798-1_bib243","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1212\/WNL.0b013e31822e7ca0","article-title":"The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study","volume":"77","author":"Jacobi","year":"2011","journal-title":"Neurology. United States"},{"key":"10.1007\/s13311-019-00798-1_bib244","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1474-4422(15)00202-1","article-title":"Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study","volume":"14","author":"Jacobi","year":"2015","journal-title":"Lancet Neurol. England"},{"key":"10.1007\/s13311-019-00798-1_bib245","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/mds.10241","article-title":"Ethnic differences in the expression of neurodegenerative disease: Machado-Joseph disease in Africans and Caucasians","volume":"17","author":"Subramony","year":"2002","journal-title":"Mov Disord. United States"},{"key":"10.1007\/s13311-019-00798-1_bib246","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jns.2015.08.019","article-title":"Planning future clinical trials in Machado Joseph disease: Lessons from a phase 2 trial","volume":"358","author":"Saute","year":"2015","journal-title":"J Neurol Sci. Netherlands"},{"key":"10.1007\/s13311-019-00798-1_bib247","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","article-title":"Scale for the assessment and rating of ataxia: development of a new clinical scale","volume":"66","author":"Schmitz-Hubsch","year":"2006","journal-title":"Neurology. United States"},{"key":"10.1007\/s13311-019-00798-1_bib248","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.10657","article-title":"Inter-rater reliability of the International Cooperative Ataxia Rating Scale (ICARS)","volume":"19","author":"Storey","year":"2004","journal-title":"Mov Disord. United States"},{"key":"10.1007\/s13311-019-00798-1_bib249","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/dmcn.13291","article-title":"Reliability and discriminant validity of ataxia rating scales in early onset ataxia","volume":"59","author":"Brandsma","year":"2017","journal-title":"Dev Med Child Neurol. England"},{"key":"10.1007\/s13311-019-00798-1_bib250","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3389\/fnhum.2017.00605","article-title":"Construct Validity and Reliability of the SARA Gait and Posture Sub-scale in Early Onset Ataxia","volume":"11","author":"Lawerman","year":"2017","journal-title":"Front Hum Neurosci. Switzerland"},{"key":"10.1007\/s13311-019-00798-1_bib251","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.msard.2017.09.032","article-title":"Validity and reliability of the International Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA) in multiple sclerosis patients with ataxia","volume":"18","author":"Salci","year":"2017","journal-title":"Mult Scler Relat Disord. Netherlands"},{"key":"10.1007\/s13311-019-00798-1_bib252","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.3760\/cma.j.issn.0366-6999.20121703","article-title":"Reliability and validity of the Chinese version of the Scale for Assessment and Rating of Ataxia","volume":"126","author":"Tan","year":"2013","journal-title":"Chin Med J (Engl). China"},{"key":"10.1007\/s13311-019-00798-1_bib253","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1590\/S0004-282X2010000200014","article-title":"Translation and validation into Brazilian version of the Scale of the Assessment and Rating of Ataxia (SARA)","volume":"68","author":"Braga-Neto","year":"2010","journal-title":"Arq Neuropsiquiatr. Brazil"},{"key":"10.1007\/s13311-019-00798-1_bib254","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/mds.21544","article-title":"Reliability and validity of the scale for the assessment and rating of ataxia: a study in 64 ataxia patients","volume":"22","author":"Weyer","year":"2007","journal-title":"Mov Disord. United States"},{"key":"10.1007\/s13311-019-00798-1_bib255","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fneur.2019.00110","article-title":"Extra-Cerebellar Signs and Non-motor Features in Chinese Patients With Spinocerebellar Ataxia Type 3","volume":"10","author":"Yuan","year":"2019","journal-title":"Front Neurol. Switzerland"},{"key":"10.1007\/s13311-019-00798-1_bib256","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13023-017-0597-1","article-title":"Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov","volume":"12","author":"Hee","year":"2017","journal-title":"Orphanet J Rare Dis. England"},{"key":"10.1007\/s13311-019-00798-1_bib257","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMe030024","article-title":"Clinical trials and rare diseases","author":"Lagakos","year":"2003","journal-title":"N. Engl. J. Med. United States;"},{"key":"10.1007\/s13311-019-00798-1_bib258","article-title":"Small Clinical Trials.","author":"Evans","year":"2001","journal-title":"Issues and Challenges."},{"key":"10.1007\/s13311-019-00798-1_bib259","first-page":"439","article-title":"Enhancing clinical evidence by proactively building quality into clinical trials","volume":"13","author":"Meeker-O'Connell","year":"2016","journal-title":"Clin Trials. SAGE Publications Sage UK: London, England"},{"key":"10.1007\/s13311-019-00798-1_bib260","article-title":"Precision medicine in spinocerebellar ataxias: treatment based on common mechanisms of disease. Ann Transl Med.","volume":"4","author":"Bushart","year":"2016","journal-title":"AME Publications"},{"key":"10.1007\/s13311-019-00798-1_bib261","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pneurobio.2013.01.001","article-title":"Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7","volume":"104","author":"Rueb","year":"2013","journal-title":"Prog Neurobiol. Elsevier"},{"key":"10.1007\/s13311-019-00798-1_bib262","first-page":"131","article-title":"Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? Lancet","volume":"351","author":"Davies","year":"1998","journal-title":"Elsevier"},{"key":"10.1007\/s13311-019-00798-1_bib263","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40263-016-0405-9","article-title":"Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain","volume":"31","author":"Patel","year":"2017","journal-title":"CNS Drugs. New Zealand"},{"key":"10.1007\/s13311-019-00798-1_bib264","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41431-018-0308-y","article-title":"Choosing not to know: accounts of non-engagement with pre-symptomatic testing for Machado-Joseph disease","volume":"27","author":"Mendes","year":"2019","journal-title":"Eur J Hum Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib265","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.tips.2013.03.004","article-title":"Challenges and opportunities of drug repositioning","volume":"34","author":"Novac","year":"2013","journal-title":"Trends Pharmacol Sci. England"},{"key":"10.1007\/s13311-019-00798-1_bib266","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bph.13798","article-title":"Drug repurposing from the perspective of pharmaceutical companies","volume":"175","author":"Cha","year":"2018","journal-title":"Br J Pharmacol. England"},{"key":"10.1007\/s13311-019-00798-1_bib267","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1080\/02640414.2016.1241421","article-title":"Chronic ingestion of a low dose of caffeine induces tolerance to the performance benefits of caffeine","volume":"35","author":"Beaumont","year":"2017","journal-title":"J Sports Sci. England"},{"key":"10.1007\/s13311-019-00798-1_bib268","first-page":"241","article-title":"Citalopram\u2014a review of pharmacological and clinical effects","volume":"25","author":"Bezchlibnyk-Butler","year":"2000","journal-title":"J Psychiatry Neurosci. Canadian Medical Association"},{"key":"10.1007\/s13311-019-00798-1_bib269","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2044.2004.03658.x","article-title":"Dantrolene\u2014a review of its pharmacology, therapeutic use and new developments","volume":"59","author":"Krause","year":"2004","journal-title":"Anaesthesia. England"},{"key":"10.1007\/s13311-019-00798-1_bib270","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/SPC.0b013e3283644c30","article-title":"Side-effects associated with targeted therapies in renal cell carcinoma","volume":"7","author":"Soulieres","year":"2013","journal-title":"Curr Opin Support Palliat Care. United States"},{"key":"10.1007\/s13311-019-00798-1_bib271","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1208\/ps050325","article-title":"Nutraceutical-definition and introduction","volume":"5","author":"Kalra","year":"2003","journal-title":"AAPS PharmSci. Springer"},{"key":"10.1007\/s13311-019-00798-1_bib272","first-page":"447","article-title":"Challenges of conducting clinical trials of natural products to combat cancer","volume":"14","author":"Paller","year":"2016","journal-title":"Clin Adv Hematol Oncol."},{"key":"10.1007\/s13311-019-00798-1_bib273","first-page":"41","article-title":"Dietary supplements: regulatory challenges and research resources","volume":"10","author":"Dwyer","year":"2018","journal-title":"Nutrients. Multidisciplinary Digital Publishing Institute"},{"key":"10.1007\/s13311-019-00798-1_bib274","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0031-6997(24)01490-X","article-title":"Clinical pharmacology of the dietary supplement creatine monohydrate","volume":"53","author":"Persky","year":"2001","journal-title":"Pharmacol Rev. ASPET"},{"key":"10.1007\/s13311-019-00798-1_bib275","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1158\/1078-0432.CCR-10-1486","article-title":"Resveratrol: challenges in translation to the clinic\u2014a critical discussion","volume":"16","author":"Subramanian","year":"2010","journal-title":"Clin Cancer Res. AACR"},{"key":"10.1007\/s13311-019-00798-1_bib276","first-page":"95","article-title":"Hsp90: a drug target? Curr Oncol Rep","volume":"12","author":"Holzbeierlein","year":"2010","journal-title":"Springer"},{"key":"10.1007\/s13311-019-00798-1_bib277","article-title":"HDAC inhibitors overcome first hurdle","author":"Garber","year":"2007","journal-title":"Nature Publishing Group;"},{"key":"10.1007\/s13311-019-00798-1_bib278","first-page":"138","article-title":"Experimental and Clinical Strategies for Treating Spinocerebellar Ataxia Type 3","volume":"371","author":"Wang","year":"2018","journal-title":"Neuroscience. United States"},{"key":"10.1007\/s13311-019-00798-1_bib279","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/14737175.2017.1364159","article-title":"Nusinersen for the treatment of spinal muscular atrophy","volume":"17","author":"Chiriboga","year":"2017","journal-title":"Expert Rev Neurother. England"},{"key":"10.1007\/s13311-019-00798-1_bib280","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/ana.25264","article-title":"Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice","volume":"84","author":"McLoughlin","year":"2018","journal-title":"Ann Neurol. United States"},{"key":"10.1007\/s13311-019-00798-1_bib281","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.omtn.2017.04.005","article-title":"Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models","volume":"7","author":"Moore","year":"2017","journal-title":"Mol Ther Nucleic Acids. United States"},{"key":"10.1007\/s13311-019-00798-1_bib282","doi-asserted-by":"crossref","first-page":"e0204438","DOI":"10.1371\/journal.pone.0204438","article-title":"Loss of the Spinocerebellar Ataxia type 3 disease protein ATXN3 alters transcription of multiple signal transduction pathways","volume":"13","author":"Zeng","year":"2018","journal-title":"PLoS One. United States"},{"key":"10.1007\/s13311-019-00798-1_bib283","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/hmg\/ddq111","article-title":"Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?","volume":"19","author":"Alves","year":"2010","journal-title":"Hum Mol Genet. England"},{"key":"10.1007\/s13311-019-00798-1_bib284","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2018.157","article-title":"RNA Interference Therapy for Machado-Joseph Disease: Long-Term Safety Profile of Lentiviral Vectors Encoding Short Hairpin RNAs Targeting Mutant Ataxin-3.","author":"Nobrega","year":"2019","journal-title":"Hum Gene Ther. United States;"},{"key":"10.1007\/s13311-019-00798-1_bib285","first-page":"2099","article-title":"Side effects of retroviral gene transfer into hematopoietic stem cells","volume":"101","author":"Baum","year":"2003","journal-title":"Blood. Am Soc Hematology"},{"key":"10.1007\/s13311-019-00798-1_bib286","first-page":"78","article-title":"Patient monitoring and follow-up in lentiviral clinical trials","volume":"15","author":"McGarrity","year":"2013","journal-title":"J Gene Med. Wiley Online Library"},{"key":"10.1007\/s13311-019-00798-1_bib287","first-page":"1","article-title":"Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications","volume":"17","author":"Wong","year":"2006","journal-title":"Hum Gene Ther. Mary Ann Liebert, Inc. 2 Madison Avenue Larchmont, NY 10538 USA"},{"key":"10.1007\/s13311-019-00798-1_bib288","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ymthe.2005.11.012","article-title":"Lentiviral vectors for use in the central nervous system","volume":"13","author":"Jakobsson","year":"2006","journal-title":"Mol Ther. Elsevier"},{"key":"10.1007\/s13311-019-00798-1_bib289","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1089\/scd.2017.0209","article-title":"CRISPR\/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells","volume":"27","author":"Ouyang","year":"2018","journal-title":"Stem Cells Dev. United States"},{"key":"10.1007\/s13311-019-00798-1_bib290","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/S0140-6736(08)60875-2","article-title":"Empowerment of patients: lessons from the rare diseases community","volume":"371","author":"Aym\u00e9","year":"2008","journal-title":"Lancet. Elsevier"},{"key":"10.1007\/s13311-019-00798-1_bib291","first-page":"154","article-title":"How do patients with rare diseases experience the medical encounter? Exploring role behavior and its impact on patient\u2013physician interaction. Health Policy (New York)","volume":"105","author":"Budych","year":"2012","journal-title":"Elsevier"},{"key":"10.1007\/s13311-019-00798-1_bib292","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/1049732315570116","article-title":"Living with and treating rare diseases: experiences of patients and professional health care providers","volume":"25","author":"Garrino","year":"2015","journal-title":"Qual Health Res. United States"},{"key":"10.1007\/s13311-019-00798-1_bib293","first-page":"307","article-title":"Patient Associations: a driving force for Rare Diseases research. Resilience: a driving force for Patient Associations. Ann Ig","volume":"30","author":"Pulciani","year":"2018","journal-title":"Italy"},{"key":"10.1007\/s13311-019-00798-1_bib294","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s11606-014-2895-9","article-title":"A systematic review of approaches for engaging patients for research on rare diseases","volume":"29","author":"Forsythe","year":"2014","journal-title":"J Gen Intern Med. Springer"},{"key":"10.1007\/s13311-019-00798-1_bib295","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1590\/1413-81232015218.19852015","article-title":"Communication strategies employed by rare disease patient organizations in Spain","volume":"21","author":"Castillo-Esparcia","year":"2016","journal-title":"Cien Saude Colet. Brazil"},{"key":"10.1007\/s13311-019-00798-1_bib296","first-page":"223","article-title":"How disease advocacy organizations participate in clinical research: a survey of genetic organizations","volume":"14","author":"Landy","year":"2012","journal-title":"Genet Med. Nature Publishing Group"},{"key":"10.1007\/s13311-019-00798-1_bib297","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1369-7625.2009.00552.x","article-title":"What, if anything, is specific about having a rare disorder? Patients' judgements on being ill and being rare","volume":"12","author":"Huyard","year":"2009","journal-title":"Heal Expect. Wiley Online Library"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00798-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-019-00798-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00798-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:44:44Z","timestamp":1761806684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923009650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":297,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1878747923009650"],"URL":"https:\/\/doi.org\/10.1007\/s13311-019-00798-1","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-019-00798-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}